Freeman Chris

Freeman Chris serves as the Chief Commercial Officer at Guardant Health, Inc., a leader in precision oncology. His role involves overseeing commercial strategies and operations within the healthcare sector, particularly focused on innovative cancer diagnostics. Between January 5, 2026, and July 2, 2026, Freeman disclosed 22 transactions, all related to Guardant Health, with a notable sale on May 26, 2026, amounting to approximately $2.9 million. His trading activity reflects a concentrated focus on Guardant Health, indicating a significant engagement with the company's market performance.